Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Armata Pharmaceuticals (ARMP) EBITDA Margin (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed EBITDA Margin for 6 consecutive years, with 339.81% as the latest value for Q4 2018.

  • Quarterly EBITDA Margin rose 1216481.0% to 339.81% in Q4 2018 from the year-ago period, while the trailing twelve-month figure was 1106.03% through Dec 2018, up 1515473.0% year-over-year, with the annual reading at 313.49% for FY2025, 44865.0% down from the prior year.
  • EBITDA Margin hit 339.81% in Q4 2018 for Armata Pharmaceuticals, down from 902.61% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 18733.01% in Q3 2014 to a low of 53927.27% in Q4 2016.
  • Historically, EBITDA Margin has averaged 6313.23% across 5 years, with a median of 2541.18% in 2015.
  • Biggest five-year swings in EBITDA Margin: soared 148276634bps in 2014 and later tumbled -5163040bps in 2016.
  • Year by year, EBITDA Margin stood at 2571.29% in 2014, then rose by 11bps to 2296.88% in 2015, then tumbled by -2248bps to 53927.27% in 2016, then soared by 78bps to 11825.0% in 2017, then surged by 103bps to 339.81% in 2018.
  • Business Quant data shows EBITDA Margin for ARMP at 339.81% in Q4 2018, 902.61% in Q3 2018, and 1124.56% in Q2 2018.